news18 February 2021 | By Hannah Balfour (European Pharmaceutical Review)
If the proof-of concept trial of AVA6000 Pro-doxorubicin is successful, it could lead to a pipeline of pro-drug chemotherapies with limited toxicity, say the drug's developers.